Burton Enright Welch’s AbbVie ABBV Stock Holding History

Burton Enright Welch’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$365K	Sell	1,452 -102	-7%	-$21.9K	0.04%	113
2026 Q1	$338K	Sell	1,554 -209	-12%	-$46.4K	0.05%	111
2025 Q4	$403K	Buy	1,763 +261	+17%	+$59.5K	0.06%	103
2025 Q3	$348K	Buy	1,502 +260	+21%	+$52.9K	0.05%	104
2025 Q2	$231K	Buy	1,242 +40	+3%	+$7.43K	0.04%	112
2025 Q1	$252K	Buy	1,202 +6	+0.5%	+$1.17K	0.05%	98
2024 Q4	$213K	Buy	1,196 +50	+4%	+$9.19K	0.04%	95
2024 Q3	$226K	Buy	+1,146	New	+$214K	0.05%	88
2024 Q2	–	Sell	-1,118	Closed	-$204K	–	93
2024 Q1	$204K	Sell	1,118 -671	-38%	-$116K	0.05%	88
2023 Q4	$277K	Buy	+1,789	New	+$261K	0.07%	70

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Burton Enright Welch's ABBV Position: Q2 2026 in Review

Burton Enright Welch reduced its AbbVie (ABBV) stake by 6.6% in Q2 2026, selling an estimated $21.9K and leaving 1,452 shares worth $365K. The position accounts for 0.04% of the portfolio, ranked #113.

Burton Enright Welch first reported a position in ABBV in Q4 2023 and has held it in 10 quarters since. The position peaked at $403K in Q4 2025. 4,208 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Burton Enright Welch held 1,452 shares of AbbVie worth $365K as of Q2 2026.
Burton Enright Welch sold 102 AbbVie shares in Q2 2026, an estimated $21.9K.
AbbVie made up 0.04% of Burton Enright Welch's portfolio in Q2 2026, its #113 holding.
Burton Enright Welch first reported a position in AbbVie in Q4 2023 and has held it in 10 quarters since.
Burton Enright Welch's AbbVie position peaked at $403K in Q4 2025.
4,208 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Burton Enright Welch's 13F filing for Q2 2026, filed 17 Jul 2026.